Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Recruiting 56Unknown 35Active not recruiting 13Terminated 8Not yet recruiting 6Completed 5Withdrawn 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Glioma 2Simpson-Golabi-Behmel syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Immunotherapy, Adoptive × Clear all
NCT03768310 2022-07-21

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Baylor College of Medicine

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02575261 2020-07-16

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

NCT02723942 2020-07-16

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT03252171 2020-07-16

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡